Royalty Pharma plc (RPRX)
Royalty Pharma plc FCF to Net Income
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|
| FCF to Net Income | 0.0% | 0.0% | (64.9%) | 124.4% | (2.2%) | 248.6% | 162.6% | 1,819.1% | 263.3% |
Royalty Pharma plc (RPRX) FCF to Net Income comparison analysis
RPRX key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
investors
worldwide
FAQ
1) What is Royalty Pharma plc's FCF to Net Income?
As of today, Microsoft Corp's last 12-month FCF to Net Income is 363.9%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for Royalty Pharma plc have been 216.1% over the past three years, and 198.2% over the past five years.
2) Is Royalty Pharma plc's FCF to Net Income Good?
As of today, Royalty Pharma plc's FCF to Net Income is 363.9%, which is higher than industry median of 84.2%. It indicates that Royalty Pharma plc's FCF to Net Income is Good.